Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: A multicenter randomized controlled trial

Journal of Chinese Integrative Medicine

Volumn 11, Issue 2, 2013, Pages 90-100

  Zhai, Xiao Feng ^a   Chen, Zhe ^a   Li, Bai ^a   Shen, Feng ^b   Fan, Jia ^c   Zhou, Wei Ping ^b   Yang, Yun Ke ^c   Xu, Jing ^d   Qin, Xiao ^d   Li, Le Qun ^e   Ling, Chang Quan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^e GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Randomized controlled trial; Recurrence; Traditional Chinese medicine; Transarterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; CINOBUFAGIN; JIEDU GRANULE; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHEMOEMBOLIZATION; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; HERBAL MEDICINE; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE REACTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER PAIN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE FREE SURVIVAL; THROMBOCYTOPENIA;

EID: 84875626667     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jintegrmed2013021     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90.
2. Ferlay J, shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008: Cancer incidence and mortality worldwide: IARC CancerBase No.10. Lyon: International Agency for Research on Cancer. 2010. (2010-01-05) [2011-01-15]. http://www.iarc.fr/en/media-centre/iarcnews/2010/ globocan2008.php.
3. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003; 237(4): 536-543.
4. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005; 42(5): 1208-1236.
5. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38(2): 200-207.
6. Jiang K, Huang ZQ, Li WH, Zhou NX, Huang XQ, Zhang WZ, Liu R. Study for the clinical and pathological factors influencing the early postoperative recurrence of the small hepatocellular carcinoma. Lin Chuang Yu Shi Yan Bing Li Xue Za Zhi. 2003; 19(3): 258-262. Chinese with abstract in English.
7. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002; 235(3): 373-382.
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003; 37(2): 429-442.
9. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000; 356(9232): 802-807.
10. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007; 245(6): 831-842.
11. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 2002; 3(10): 593-603.
12. Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009; (1): CD001199.
13. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005; 16(4): 655-663.
14. Gupta D, Lis CG, Birdsall TC, Grutsch JF. The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer. 2005; 13(11): 912-919.
15. Wu MC. Traditional Chinese medicine in prevention and treatment of liver cancer: function, status and existed problems. J Chin Integr Med. 2003; 1(3): 163-164. Chinese.
16. Deng G, Cassileth BR, Yeung KS. Complementary therapies for cancer-related symptoms. J Support Oncol. 2004; 2(5): 419-426; discussion 427-419.
17. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res. 2004; 24(1): 303-309.
18. Qi F, Li A, Zhao L, Xu H, Inagaki Y, Wang D, Cui X, Gao B, Kokudo N, Nakata M, Tang W. Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. J Ethnopharmacol. 2010; 128(3): 654-661.
19. Xin HL, Yue XQ, Xu YF, Wu YC, Zhang YN, Wang YZ, Ling CQ. Two new polyoxygenated triterpenoids from Actinidia valvata. Helvetica Chimica Acta. 2008; 91(3): 575-580.
20. Shim JS, Kim JH, Lee J, Kim SN, Kwon HJ. Anti-angiogenic activity of a homoisoflavanone from Cremastra appendiculata. Planta Med. 2004; 70(2): 171-173.
21. Liu CP, Wang XS, Fang JN. Chemical studies on two acidic polysaccharides from Salvia chinensis. Zhong Cao Yao. 2004; 35(1): 8-12. Chinese with abstract in English.
22. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009; 115(22): 5309-5318.
23. Yu Y, Lang Q, Chen Z, Li B, Yu C, Zhu D, Zhai X, Ling C. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer. 2009; 115(22): 5132-5138.
24. Chen Z, Li B, Yue X, Zhu D, Yu C, Wu M, Ling C. A retrospective controlled analysis of outcomes of using integrated therapy of traditional Chinese and modern medicines for primary liver cancer of middle and late stages. J Altern Complement Med. 2006; 12(10): 941-942.
25. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649-655.
26. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001; 134(8): 663-694.
27. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M, Sassa T. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997; 25(1): 87-92.
28. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CECAE) V 3.0. DCTD, NCI, NIH, DHHS. 3, 31, 2003. (2006-08-09) [2010-07-15]. http://ctep.cancer.gov/protocolDevelopment/electronic_ applications/docs/ctcaev3.pdf.
29. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med. 1999; 18(15): 1905-1942.
30. Strategy for model selection. In: Collett D. Modelling survival data in medical research. London: Chapman & Hall. 1994: 78-86.
31. Wei ZH, Pu J, Ma YF, Wang jC, Lu GM, Wei BN. Clinical research on the recrudesce and prognosis of liver cancer with TACE. Youjiang Yi Xue. 2011; 39(4): 403-405. Chinese with abstract in English.
32. Su YH, Yin XC, Xie JM, Gao B, Ling CQ. Inhibition effects of three kinds of bufotoxins on human SMMC-7721 and BEL-7402 hepatoma cells lines. Di Er Jun Yi Da Xue Xue Bao. 2003; 24(4): 393-395. Chinese with abstract in English.
33. Han KQ, Gu W, Su YH, Huang XQ, Wang X, Ling CQ. Anti-tumor effects of bufalin on the orthotopic transplantation tumor model of hepatocellular carcinoma in mice. Zhonghua Shi Yan Wai Ke Za Zhi. 2004; 21(12): 1436-1438. Chinese with abstract in English.
34. Cui X, Inagaki Y, Xu H, Wang D, Qi F, Kokudo N, Fang D, Tang W. Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2. 2.15 cells. Biol Pharm Bull. 2010; 33(10): 1728-1732.
35. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008; 48(Suppl 1): S20-S37.
36. Ling CQ. Problems in cancer treatment and major research of integrative medicine. J Chin Integr Med. 2003; 1(3): 168-170. Chinese with abstract in English.